% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Baertsch:132529,
      author       = {M.-A. Baertsch and M. Hundemer and J. Hillengass$^*$ and H.
                      Goldschmidt and M.-S. Raab$^*$},
      title        = {{T}herapeutic monoclonal antibodies in combination with
                      pomalidomide can overcome refractoriness to both agents in
                      multiple myeloma: {A} case-based approach.},
      journal      = {Hematological oncology},
      volume       = {36},
      number       = {1},
      issn         = {0278-0232},
      address      = {New York, NY [u.a.]},
      publisher    = {Wiley Interscience},
      reportid     = {DKFZ-2018-00213},
      pages        = {258 - 261},
      year         = {2018},
      abstract     = {In multiple myeloma (MM), the synergy between
                      immunomodulatory drugs (IMiDs) and monoclonal antibodies
                      (MABs) has been demonstrated in several pivotal trials.
                      However, disease refractory to either class of compounds
                      remains a major therapeutic challenge. We here report on 3
                      heavily pretreated MM patients who were refractory to
                      pomalidomide as well as to MABs against CD38 (daratumumab)
                      or CD20 (rituximab), respectively, but who responded to
                      retreatment with the same agents in combination. Responses
                      were durable with PFS of 7, 10 (ongoing), and 30 months
                      from initiation of combination treatment. The combination of
                      IMiDs with MABs directed against MM cell surface antigens
                      can overcome refractoriness to both agents.},
      cin          = {E010 / G170},
      ddc          = {610},
      cid          = {I:(DE-He78)E010-20160331 / I:(DE-He78)G170-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28840598},
      doi          = {10.1002/hon.2473},
      url          = {https://inrepo02.dkfz.de/record/132529},
}